News Protalix BioTherapeutics, Inc.

Stocks

PLX

US74365A3095

Pharmaceuticals

Market Closed - NYSE 01:00:00 04/11/2026 +04			5-day change	1st Jan Change
2.610 ^USD	+1.95%		+3.16%	+45.00%

09-16	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
08-12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026

All News

Mentions Relevance

11-03	Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026	PR
10-26	Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference	PR
09-16	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
09-08	Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences	PR
08-12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Protalix: Q2 Earnings Snapshot	AQ
08-12	Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results	PR
08-12	Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026	CI
08-05	Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026	PR
05-13	Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
05-13	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)	PU
05-13	Protalix: Q1 Earnings Snapshot	AQ
05-13	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results	PR
05-13	Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026	CI
05-06	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026	PR
03-19	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa	CI
03-18	Top Midday Decliners	MT
03-18	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-18	Protalix BioTherapeutics, Inc., 2025 Earnings Call, Mar 18, 2026
03-18	Protalix BioTherapeutics, Inc. Provides Earnings Guidance for the Year 2026	CI
03-18	Protalix Biotherapeutics reports fiscal year 2025 financial and business results	RE
03-18	Protalix: Q4 Earnings Snapshot	AQ
03-18	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results	PR